Biogen - 30 Year Stock Price History | BIIB

Historical daily share price chart and data for Biogen since 1991 adjusted for splits. The latest closing stock price for Biogen as of October 22, 2021 is 264.80.
  • The all-time high Biogen stock closing price was 475.98 on March 20, 2015.
  • The Biogen 52-week high stock price is 468.55, which is 76.9% above the current share price.
  • The Biogen 52-week low stock price is 223.25, which is 15.7% below the current share price.
  • The average Biogen stock price for the last 52 weeks is 290.03.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Biogen Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2021 298.8833 242.9500 414.7100 242.9500 264.8000 8.14%
2020 285.3138 294.2400 355.6300 236.2600 244.8600 -17.48%
2019 263.5519 304.6900 338.9600 216.7100 296.7300 -1.39%
2018 313.6443 334.1700 383.8300 257.5200 300.9200 -5.54%
2017 291.0549 291.7100 344.5800 246.5400 318.5700 12.34%
2016 280.1990 294.6200 330.1100 224.6000 283.5800 -7.43%
2015 352.5829 342.0100 475.9800 256.0400 306.3500 -9.75%
2014 317.9830 280.3300 360.6700 273.5175 339.4500 21.42%
2013 215.2810 150.0000 295.8800 142.8200 279.5720 91.00%
2012 136.5151 113.5000 156.0600 113.5000 146.3700 33.00%
2011 91.9759 67.2000 118.7200 65.0800 110.0500 64.13%
2010 56.3579 53.6400 68.2200 46.2200 67.0500 25.33%
2009 48.9437 48.4900 53.7000 42.1300 53.5000 12.32%
2008 55.4272 55.8700 71.3800 39.0200 47.6300 -16.32%
2007 56.5874 49.3300 82.5100 43.1300 56.9200 15.71%
2006 45.9898 46.7400 52.2600 40.7300 49.1900 8.64%
2005 43.2715 66.2900 67.8000 33.3500 45.2800 -32.02%
2004 57.2480 36.9400 67.9200 36.9400 66.6100 81.50%
2003 34.4312 34.3400 41.5700 28.0900 36.7000 10.64%
2002 47.4686 68.1500 70.9600 30.1500 33.1700 -51.88%
2001 56.9957 59.2500 74.5700 35.6900 68.9300 9.09%
2000 44.2699 31.0833 75.0833 19.1267 63.1867 92.94%
1999 14.0875 7.7917 32.7500 6.8550 32.7500 318.09%
1998 5.4740 5.6450 8.0200 2.9167 7.8333 36.71%
1997 4.6884 3.7500 7.6667 2.7083 5.7300 44.76%
1996 3.7283 3.1867 5.0200 2.4367 3.9583 21.79%
1995 1.1416 0.3950 3.8550 0.3750 3.2500 815.49%
1994 0.5854 0.9367 1.0833 0.3550 0.3550 -62.96%
1993 0.9571 1.5000 1.5000 0.6250 0.9583 -34.29%
1992 1.6281 2.1250 3.3333 1.0417 1.4583 -32.69%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $38.897B $13.445B
Biogen is a leading biopharmaceutical company engaged in the research, development and marketing of targeted therapies for the treatment of cancer, autoimmune and inflammatory diseases. The company owns industry leading brands for the treatment of multiple sclerosis, next-generation treatments for hemophilia, and a deep clinical pipeline ranging from Alzheimer's disease, lupus nephritis to neuropathic pain.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76